NYU Langone Presenters Reveal Significant Epilepsy Breakthrough and Misinformation Strategies at AAN 2026 Chicago Meeting

Discover new Phase 3 epilepsy trial results and strategies against medical misinformation presented by NYU Langone at the 2026 AAN meeting.

By: AXL Media

Published: Apr 20, 2026, 8:12 AM EDT

Source: Information for this report was sourced from EurekAlert

A Major Academic Presence at the Premier Neurological Summit

The 2026 American Academy of Neurology Annual Meeting in Chicago serves as the backdrop for a massive research showcase from NYU Langone Health, with faculty and students delivering more than 80 distinct presentations. According to Steven L. Galetta, MD, the chair of neurology at NYU Grossman School of Medicine, the volume of work presented reflects a deep commitment to scientific discovery that directly impacts patient care. This significant presence at the April 18 to 22 conference underscores the institution's position as a leading center for neurosurgery and neurology, operating across 18 specialized divisions and centers to advance the field.

Significant Clinical Success for Next Generation Epilepsy Treatment

Among the most impactful findings presented is the success of the X-TOLE2 Phase 3 clinical trial, which evaluated the efficacy of azetukalner in treating focal onset seizures. Jacqueline A. French, MD, an epileptologist at NYU Langone, reported that the trial achieved high statistical significance, with a 25 milligram dose resulting in a 53.2 percent median reduction in seizures compared to just 10.4 percent for the placebo group. The oral medication, which requires only once daily dosing and avoids complex titration, is being positioned as a streamlined therapeutic option for patients who have struggled with traditional seizure management protocols.

Confronting the Spread of Harmful Medical Myths and Misinformation

Addressing the sociological challenges of modern medicine, Jonathan E. Howard, MD, presented a platform talk focused on neutralizing medical misinformation that currently threatens patient outcomes. Dr. Howard, who directs the neurology service at Bellevue Hospital, emphasized that care quality is frequently compromised by pervasive medical myths circulating within the community. His research outlines specific, practical strategies for practitioners to re-establish accurate information channels, ensuring that patients make health decisions based on scientific reality rather than unverified digital claims or historical misconceptions.